Iron Deficiency Anemia Treatment with Ferric Derisomaltose

Dosing and Administration

• For patients weighing ≥50 kg with hemoglobin >10 g/dL, the European Society of Cardiology recommends administering 1000 mg of ferric derisomaltose as a single dose 1
• For patients weighing ≥50 kg with hemoglobin ≤10 g/dL, the European Society of Cardiology and the International Society of Nephrology recommend administering 1500 mg as a single dose 1, 2
• For patients weighing <50 kg with hemoglobin >10 g/dL, the European Society of Cardiology recommends administering 500 mg as a single dose 1
• For patients weighing <50 kg with hemoglobin ≤10 g/dL, the European Society of Cardiology recommends administering 1000 mg as a single dose 1
• Administer ferric derisomaltose as an intravenous infusion over at least 20 minutes for doses ≤1000 mg, as recommended by the International Society of Nephrology 2
• For doses >1000 mg, the International Society of Nephrology recommends administering over 30 minutes or more 2

Monitoring and Follow-up

• Check ferritin and transferrin saturation at next scheduled visit, preferably after 3 months, as recommended by the European Society of Cardiology 1
• Monitor for recurrent iron deficiency every 3 months for at least a year after correction, and between 6 and 12 months thereafter, as recommended by the European Crohn’s and Colitis Organisation 3
• Re-treatment with IV iron should be initiated as soon as serum ferritin drops below 100 μg/L or hemoglobin below 12 g/dL (women) or 13 g/dL (men), as recommended by the European Crohn’s and Colitis Organisation 3

Special Considerations

• Do not administer IV iron if hemoglobin >15 g/dL, as recommended by the European Society of Cardiology 1
• For patients with chronic kidney disease, dosing is based on body weight (20 mg/kg), as recommended by the International Society of Nephrology 2
• In patients with inflammatory bowel disease, aim for post-treatment serum ferritin levels of up to 400 μg/L to prevent recurrence of iron deficiency, as recommended by the European Crohn’s and Colitis Organisation 3

Iron Deficiency Anemia Treatment with Ferric Derisomaltose

Dosing and Administration

• The American Journal of Hematology recommends repeat dose if iron deficiency anemia recurs 4

Advantages of Ferric Derisomaltose

• Ferric derisomaltose is the only IV iron formulation with FDA approval for total dose infusion, according to the American Journal of Hematology 5, 6
• Demonstrates a statistically significant reduction in death from cardiovascular events in patients with congestive heart failure, as reported by the American Journal of Hematology 6

Follow-up Monitoring

• Laboratory evaluation following IV iron should include a complete blood count (CBC) and iron parameters (ferritin, percent transferrin saturation) 4 to 8 weeks after infusion, as recommended by the American Journal of Hematology 5
• Do not evaluate iron parameters within the first 4 weeks after administration, according to the American Journal of Hematology 5

Clinical Context

• Effective across multiple conditions including chronic kidney disease, pregnancy, inflammatory bowel disease, and congestive heart failure, as reported by the American Journal of Hematology 6
• Frequency of administration depends on the underlying etiology of iron deficiency; a single total dose infusion may suffice if the cause has been eliminated, according to the American Journal of Hematology 6

Iron Deficiency Anemia Treatment with Ferric Derisomaltose

Patient Indications and Assessment

• The patient likely has malabsorption, which is a clear indication for IV iron therapy per Aetna CPB criteria 7
• Patient has an unsatisfactory response to oral iron administration, as evidenced by persistent severe anemia despite oral iron therapy 7
• Patient has a disorder of the gastrointestinal tract with decreased absorption, which is specifically listed as an indication in the Aetna criteria 7

Monitoring and Treatment Outcomes

• Iron parameters should not be evaluated within the first 4 weeks after administration as circulating iron can interfere with assay results 7
• Hemoglobin concentrations should increase within 1-2 weeks of treatment and should increase by 1-2 g/dL within 4-8 weeks of therapy 7

Iron Deficiency Anemia Treatment with Ferric Derisomaltose

Target Parameters for Iron Repletion

• The American Society of Hematology recommends target parameters of transferrin saturation >20% and serum ferritin >100 ng/mL (but preferably not exceeding 500 mg/L to avoid toxicity) for iron repletion in patients with iron deficiency anemia 8

Monitoring and Follow-up

• The European Renal Association recommends checking complete blood count and iron parameters (ferritin, transferrin saturation) at 4-8 weeks post-infusion and monitoring hemoglobin and red cell indices at 3-month intervals for the first year after iron repletion 8

Ferric Derisomaltose Dosing and Monitoring

Monitoring and Re-Dosing

• For patients with chronic conditions and ongoing iron losses, such as inflammatory bowel disease (IBD), recurrence is common and repeat dosing will be necessary, with monitoring every 3 months for at least 1 year after correction, and then every 6 months between 6-12 months thereafter, according to the Journal of Crohn's and Colitis 9
• In IBD patients, post-treatment ferritin levels >400 μg/L can prevent recurrence for 1-5 years better than lower levels, as reported by the Journal of Crohn's and Colitis 9

Comparison with Other IV Iron Formulations

• Ferric derisomaltose has a practical advantage over other IV iron formulations, such as iron sucrose, with a single 1500mg dose eliminating the need for multiple clinic visits, as noted in the Journal of Crohn's and Colitis 9

Practical Advantages and Dosing Considerations for Ferric Derisomaltose (Monoferric) versus Iron Sucrose (Venofer) in Non‑Dialysis CKD

Administration Efficiency

Formulation Concentration

Iron Sucrose Dosing Protocol

Evidence source: observational dosing data reported in Kidney International (2021) 10 (no formal grading provided).

Infection Contraindication